Email Updates

You are here

PrEP

PrEP works. Investment in more options must continue, and faster, smarter rollout must be a top priority.

Clinical trials have shown that different types of pre-exposure prophylaxis (PrEP) using antiretroviral (ARV) drugs dramatically reduce the risk of HIV infection for people who take it as directed. While PrEP won’t be right for every individual at risk for HIV, millions will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal. Meanwhile the landscape is changing as more options move through research, regulatory review or enter the market, intensifying the need to improve implementation.

TDF/FTC (brand name Truvada) was first approved for use as oral PrEP in 2012, now dozens of countries have approved it, but PrEP still has not reached many of the people who need it most. In 2019, F/TAF (brand name Descovy) became the 2nd oral PrEP product to be approved, but only for men who have sex with men (MSM) and transgender women. Efficacy studies of F/TAF among cisgender women are ongoing. Findings reported in 2020 show injectable cabotegravir is safe and effective and the product is undergoing regulatory review. For more information go to our dedicated pages on cabotegravir on AVAC.org and PrEPWatch.

For all these interventions and other ARVs still in the R&D pipeline, advocacy is crucial: There must be continued investment in the development of additional options, community engagement must be integrated from trial design to implementation, and improved programming must support those who need HIV prevention options the most.

Key Update

Over the weekend, we at AVAC and allies around the world witnessed history and gained hope as the results of the American presidential election (finally) got announced. News also came in that the HPTN 084 trial of injectable long-acting cabotegravir for HIV prevention in cisgender women found a high level of effectiveness at a scheduled interim data review.

November 9, 2020
AVAC
What We're Reading

A promotional program designed to educate patients on HIV risk and prevention saw use of a preventive drug regimen among at-risk groups in Africa increase by more than 50 percent, according to a study published Wednesday by the journal Science Translational Medicine.

September 23, 2020
UPI

A small but significant proportion of gay and bisexual men with prescriptions for HIV pre-exposure prophylaxis (PrEP) have been sharing their medication with others, a new study finds.

September 14, 2020
Medscape

The daily drug regimen known as PrEP is a nearly foolproof way to prevent HIV infection. But a new study suggests that many high-risk Americans may be giving the medication a pass because of cost.

September 10, 2020
US News & World Report
Subscribe to RSS - PrEP